OncoHost to Present New PROphetNSCLC® Data at WCLC 2026 Demonstrating Predictive Performance Beyond Baseline Sampling
New findings support the applicability of PROphetNSCLC® following chemo or immunotherapy-based cycle, potentially broadening its real-world clinical utility BINYAMINA, Israel and CARY, N.C., Sept. 10, 2026 /PRNewswire/ -- OncoHost, a technology company transforming precision oncology...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia
- JACC: Clinical Electrophysiology veröffentlicht die 12-Monats-Ergebnisse der ersten Field PULSE-Studie am Menschen von Field Medical: 94,2 % PVI-Haltbarkeit pro Vene bei optimierter Wellenform
- JACC: Clinical Electrophysiology publie les résultats à 12 mois du premier essai Field PULSE chez l'humain de Field Medical : 94,2 % de durabilité de l'isolement des veines pulmonaires, par veine, grâce à une forme d'onde optimisée
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →